coxsackieviru
common
pathogen
myocard
previous
synthes
sirna
target
proteas
gene
achiev
reduct
replic
vitro
howev
like
drug
develop
sirna
face
major
challeng
target
deliveri
studi
investig
novel
approach
deliv
sirna
specif
cell
popul
eg
hela
cell
contain
folat
receptor
use
receptor
ligand
folat
link
packag
rna
prna
bacteri
phage
prna
monom
spontan
form
dimer
multim
optim
condit
basepair
stem
loop
coval
link
fluorescencetag
folat
deliv
conjug
specif
hela
cell
without
need
transfect
demonstr
prna
coval
conjug
achiev
equival
antivir
effect
alon
final
drug
target
deliveri
evalu
use
prna
monom
dimer
carri
folat
ligand
demonstr
strongli
inhibit
replic
data
indic
prna
sirna
carrier
specif
deliv
drug
target
cell
via
ligand
specif
receptor
interact
inhibit
viru
replic
effect
epidemiolog
studi
report
coxsacki
group
b
virus
particularli
strain
primari
causal
agent
human
myocard
kim
et
al
diseas
often
enter
late
phase
dilat
cardiomyopathi
patient
dilat
cardiomyopathi
usual
progress
termin
heart
failur
requir
heart
transplant
last
therapeut
option
martino
et
al
present
specif
treatment
diseas
posit
singlestrand
rna
viru
infect
host
cell
coxsacki
adenoviru
receptor
car
bergelson
et
al
viral
genom
encod
four
capsid
protein
seven
nonstructur
protein
includ
two
proteas
rnadepend
rna
polymeras
rna
directli
translat
singl
polyprotein
subsequ
process
mainli
viral
proteas
produc
matur
structur
nonstructur
protein
viral
replic
klump
et
al
thu
viral
proteas
play
crucial
role
viral
life
cycl
pathogenesi
chau
et
al
xiong
et
al
reason
viral
proteas
one
major
target
antivir
drug
design
recent
develop
therapeut
viral
myocard
focus
small
interf
rna
sirna
target
viral
mrna
inhibit
translat
sirna
short
doublestrand
rna
dsrna
molecul
target
specif
sequenc
mrna
degrad
via
cellular
process
known
rna
interfer
rnai
dorsett
tuschl
process
sirna
incorpor
rnainduc
silenc
complex
risc
recogn
cleav
target
sequenc
elbashir
et
al
previous
synthes
sirna
target
proteas
gene
achiev
inhibit
replic
although
new
strategi
excit
potenti
like
parallel
drug
develop
one
major
barrier
clinic
applic
nonspecif
distribut
drug
bodi
administr
studi
investig
novel
approach
deliv
sirna
suscept
target
cell
use
ligandlink
prna
packag
rna
vehicl
prna
one
six
copi
rna
compon
within
nanomotor
bacteri
phage
discov
year
ago
guo
et
al
howev
potenti
applic
drug
packag
deliveri
attract
scientist
attent
recent
prna
nucleotid
nt
long
found
play
essenti
role
phage
dna
packag
prna
molecul
form
dimer
trimer
ultim
hexam
array
handinhand
interact
right
left
interlock
loop
guo
guo
et
al
structur
featur
prna
allow
easi
manipul
permit
convers
prna
gene
target
deliveri
vehicl
sinc
molecul
smaller
present
use
dna
vector
facilit
cellular
intern
confer
lower
immunogen
larg
vector
multim
structur
prna
complex
allow
carri
therapeut
molecul
ligand
simultan
may
enabl
deliv
drug
specif
target
cell
popul
guo
prna
molecul
contain
two
independ
fold
domain
distinct
function
replac
insert
oligonucleotid
preced
nt
follow
nt
interfer
format
dimer
long
strand
pair
therefor
proxim
doublestrand
helic
region
prna
redesign
carri
addit
sequenc
without
alter
secondari
structur
intermolecular
interact
guo
base
characterist
replac
helic
region
doubl
strand
deliv
therapeut
molecul
target
cell
via
prna
vehicl
search
ligand
guid
drug
specif
deliveri
mani
molecul
rna
aptam
peptid
antibodi
test
kumar
et
al
maruyama
et
al
terada
et
al
studi
use
folic
acid
ligand
deliveri
hela
cell
suscept
host
cell
express
folat
receptor
folic
acid
vitamin
essenti
biosynthesi
nucleotid
produc
mammalian
cell
consum
elev
quantiti
prolifer
cell
transport
across
plasma
membran
use
either
membraneassoci
reduc
folat
carrier
folat
receptor
fr
reddi
low
former
found
virtual
cell
latter
found
primarili
polar
epitheli
cell
activ
macrophag
reduc
folat
carrier
probabl
capabl
intern
necessari
folat
normal
cell
howev
fr
frequent
overexpress
wide
rang
tumor
cell
consequ
increas
folat
requir
lu
low
toffoli
et
al
therefor
fr
natur
ligand
folic
acid
becom
popular
molecul
target
attach
drug
cancer
cell
studi
construct
folatelabel
prna
monom
form
heterodim
chimer
one
subunit
dimer
contain
folateamp
end
use
target
cell
recognit
harbor
moieti
therapeut
design
specif
deliv
incub
rather
transfect
hela
cell
via
folatefr
interact
prnacarri
molecul
strongli
inhibit
replic
achiev
antivir
effici
equival
free
deliv
transfect
indic
function
properli
process
releas
enter
target
cell
importantli
approach
specif
deliv
drug
target
cell
folat
receptor
neg
cell
indic
promis
drug
target
deliveri
treat
cancer
infecti
diseas
sirna
target
proteas
gene
synthes
qiagenxeragon
germantown
md
describ
previous
final
concentr
sirna
provid
buffer
control
prnasirna
synthes
vitro
transcript
cdna
fragment
encod
chimer
prnasirna
cdna
fragment
produc
pcr
follow
standard
procedur
use
previous
construct
plasmid
prna
dna
nt
prna
dna
prna
dna
templat
specif
design
primer
yang
et
al
zhang
et
al
end
primer
contain
phage
promot
sequenc
follow
sens
sequenc
sirna
end
primer
contain
antisens
sequenc
sirna
primer
sequenc
use
list
tabl
underlin
sequenc
phage
promot
sequenc
shade
area
sens
antisens
strand
sirna
sequenc
bold
nt
indic
singl
point
mutat
middl
region
sequenc
use
gener
prnasirnamut
control
anoth
control
prnasirnascr
gener
use
primer
contain
scrambl
sirna
sequenc
folateamp
use
label
prna
synthes
trilink
biotechnolog
usa
synthes
variou
control
prnasirna
vitro
transcript
conduct
use
kit
ambion
describ
previous
guo
et
al
briefli
pcr
amplifi
cdna
templat
contain
phage
promot
transcrib
rna
polymeras
presenc
atp
gtp
utp
ctp
mm
transcript
product
purifi
polyacrylamid
gel
electrophoresi
page
elut
sodium
acet
mm
edta
sodium
dodecyl
sulfat
sd
rna
ethanol
precipit
resuspend
steril
depctreat
water
label
prna
folat
mm
folateamp
mm
atp
includ
transcript
reaction
togeth
mm
utp
ctp
gtp
solut
also
contain
mm
tri
ph
mm
mgcl
mm
spermidin
triton
mm
dtt
mm
dna
templat
uml
rna
polymeras
promega
folat
link
amp
use
initi
chain
extens
transcript
thu
ensur
label
occur
end
prna
transcript
magnesium
mm
includ
buffer
maintain
fold
prna
format
dimer
vitro
transcript
product
prna
chimer
analyz
denatur
page
describ
previous
guo
brief
denatur
polyacrylamid
gel
prepar
use
gel
run
buffer
prepar
rna
sampl
equal
volum
gel
load
buffer
ii
ambion
ad
sampl
contain
rna
heat
min
load
gel
run
h
gentli
agit
min
gelr
biotium
ca
ddh
prna
heterodim
prepar
mix
folateprna
control
prnasirna
vitro
transcript
product
molar
ratio
solut
contain
mm
mgcl
rnase
rnase
inhibitor
mm
dtt
rt
buffer
contain
mm
tri
hcl
ph
mm
nacl
mm
edta
prna
heterodim
format
confirm
nativepag
polyacrylamid
gel
pour
without
sd
run
electrod
buffer
trishcl
glycin
ph
produc
fulllength
cdna
clone
genbank
access
provid
reinhardt
kandolf
univers
tubingen
germani
amplifi
hela
cell
american
type
cultur
collect
transfect
viru
titer
routin
determin
begin
experi
plaqu
assay
hela
cell
mous
embryo
fibroblast
mef
cell
cultur
folatefre
medium
gibco
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
invitrogen
co
incub
serum
provid
normal
complement
endogen
folat
cell
growth
transfect
chimer
perform
optim
condit
briefli
cell
grown
overnight
cell
reach
confluenc
wash
overlaid
transfect
complex
contain
pmol
sirna
oligofectamin
invitrogen
overnight
follow
transfect
cell
wash
infect
moi
multipl
infect
incub
co
h
cell
lysat
collect
assay
inhibit
replic
chimer
prnasirna
label
p
atp
end
use
polynucleotid
kinas
follow
supplier
instruct
new
england
biolab
label
prnasirna
product
process
dicer
digest
briefli
reaction
solut
contain
sirna
unit
recombin
rnaspecif
endonucleas
dicer
genlanti
san
diago
ca
incub
differ
period
time
process
sirna
confirm
denatur
polyacrylamideurea
gel
electrophoresi
hela
cell
mef
cell
noncanc
cell
low
number
folic
acid
receptor
maintain
folic
aciddefici
rpmi
medium
two
week
consum
remain
folat
insid
cell
subcultur
two
plate
contain
without
contain
folat
respect
incub
overnight
fitcfol
acid
conjug
ad
cell
cultur
medium
final
concentr
h
incub
green
fluoresc
signal
distribut
cell
observ
fluoresc
microscop
local
bind
distribut
fitcfol
surfac
insid
cell
cell
nuclei
counterstain
dapi
molecular
probe
hela
cell
maintain
folatefre
rpmi
medium
two
week
one
day
experi
hela
cell
seed
sixwel
plate
folatefre
rpmi
medium
wash
phosphatebuff
salin
pb
contain
mm
mgcl
premad
monom
folateprna
heterodim
contain
rnase
inhibitor
ambion
ad
cell
cultur
incub
h
incub
free
rna
wash
cell
infect
moi
h
cell
lysat
supernat
collect
analyz
replic
effici
rtpcr
western
blot
viral
plaqu
assay
prna
vector
prnasirnamut
prnasirna
scr
use
control
cell
line
suscept
folic
acid
receptor
neg
avail
thu
far
abl
includ
one
cell
line
addit
control
antivir
evalu
total
rna
extract
cell
indic
time
point
posttransfect
pt
post
incub
use
rneasi
kit
qiagen
extract
rna
treat
dnase
remov
residu
dna
revers
transcript
rt
conduct
accord
manufactur
instruct
invitrogen
use
extract
rna
hexam
primer
follow
pcr
amplifi
cdna
pcr
reaction
mixtur
contain
rt
product
sens
antisens
primer
reaction
run
cycl
standard
paramet
yang
et
al
pcr
primer
sequenc
clone
gene
mention
pcr
product
sampl
analyz
agaros
gel
electrophoresi
protein
concentr
sampl
quantifi
bradford
assay
use
fatfreebovin
serum
albumin
bsa
standard
western
blot
analysi
perform
standard
protocol
previous
describ
equal
amount
protein
subject
sdspage
transfer
onto
nitrocellulos
membran
hybond
edl
amersham
molecular
weight
protein
estim
comparison
benchmark
prestain
protein
ladder
invitrogen
load
membran
block
skim
milk
contain
tween
h
blot
probe
primari
mous
antibodi
capsid
protein
dako
sigma
h
follow
incub
horseradishperoxidaseconjug
goat
secondari
antibodi
antimous
immunoglobulin
g
dilut
bd
bioscienc
final
express
detect
ecl
reagent
amersham
viru
titer
determin
plaqu
assay
describ
previous
yuan
et
al
briefli
hela
cell
seed
plate
cellswel
incub
h
cell
confluenc
reach
approxim
cell
wash
pb
overlaid
dilut
supernat
cultur
cell
incub
min
supernat
remov
final
cell
overlaid
ml
steril
soft
bactoagarminim
essenti
medium
cell
incub
h
fix
carnoy
fix
min
stain
crystal
violet
plaqu
count
amount
plaqu
form
unit
pfu
ml
calcul
cell
viabil
measur
use
salt
mt
assay
kit
promega
accord
manufactur
instruct
hela
cell
grown
plate
overnight
incub
prnasirna
monom
heterodim
concentr
describ
h
cell
infect
overnight
follow
ad
mt
reagent
use
protocol
per
manufactur
instruct
clontech
cell
incub
h
absorb
formazan
measur
nm
use
enzymelink
immunosorb
assay
elisa
reader
quantiti
formazan
product
directli
proport
number
viabl
cell
cultur
medium
surviv
valu
absorb
nontreat
shaminfect
cell
defin
remain
data
cell
includ
sirnatr
controltr
nontreat
cell
convert
ratio
nontreat
shaminfect
sampl
addit
morpholog
chang
cell
follow
infect
evalu
phasecontrast
microscopi
prna
contain
doublestrand
helic
domain
end
intermolecular
bind
domain
fold
independ
zhang
et
al
fig
complementari
modif
studi
reveal
alter
primari
sequenc
nucleotid
helic
region
prna
affect
structur
fold
long
two
strand
basepair
chen
et
al
zhang
et
al
sirna
dsrna
helix
replac
helic
region
prna
carri
prna
molecul
construct
chimer
prnasirna
plasmid
encod
prna
backbon
sequenc
construct
previous
clone
synthes
dsdna
fragment
plasmid
vector
zhang
et
al
plasmid
use
templat
conduct
pcr
amplifi
cdna
fragment
encod
chimer
prnasirna
contain
order
sens
sequenc
sirna
polya
liker
prna
sequenc
ploya
linker
antisens
sequenc
sirna
fig
cdna
fragment
analyz
agaros
gel
electrophoresi
fig
vitro
transcript
use
pcramplifi
cdna
fragment
contain
phage
promot
upstream
insert
conduct
use
rna
polymeras
chimer
prna
transcript
harbor
sequenc
shown
fig
chimer
prna
synthes
includ
prna
chimera
harbor
sirna
target
proteas
gene
ii
prnasirnamut
prna
chimera
contain
point
mutat
middl
region
sirna
iii
prnasirnascr
carri
scrambl
sirna
addit
prna
vector
nt
also
synthes
use
control
chimer
prnasirna
analyz
denatur
ureapag
fig
folat
label
prna
achiev
util
folateamp
initi
rna
transcript
phage
promot
publish
condit
huang
et
al
promot
produc
superior
homogen
rna
phage
promot
compar
total
rna
yield
huang
et
al
huang
et
al
folateamp
use
initi
chain
extens
ensur
label
occur
transcript
vitro
transcript
perform
presenc
folateamp
atp
togeth
ctp
utp
gtp
studi
best
molar
ratio
folateamp
atp
consid
total
yield
rna
product
percentag
prna
carri
folat
label
compar
ratio
use
previous
guo
et
al
transcript
use
molar
ratio
produc
even
higher
yield
rna
transcript
requir
gel
purif
could
directli
use
dimer
format
rna
label
folat
slower
migrat
rate
nonlabel
rna
denatur
polyacrylamid
gel
dna
also
use
templat
vitro
transcript
presenc
folateamp
gener
chimer
monom
increas
access
folat
molecul
folat
receptor
cell
surfac
folatelabel
prna
design
overhang
nt
prna
truncat
guo
et
al
folatelabel
prna
vector
could
form
heterodim
chimera
achiev
specif
deliveri
gel
electrophoresi
result
indic
optim
transcript
condit
prna
contain
folat
moieti
fig
extens
studi
prna
reveal
two
prna
subunit
form
dimer
interact
complementari
leftand
righthand
loop
prna
monom
guo
et
al
sequenc
respons
intermolecular
prnaprna
interact
studi
locat
nt
fig
prna
contain
righthand
loop
g
g
c
lefthand
loop
u
g
c
g
togeth
pair
lefthand
loop
c
c
u
g
righthand
loop
b
c
g
c
prna
respect
chimer
monom
subunit
intent
design
possess
either
match
use
prna
dna
templat
synthes
prnasirna
prna
dna
templat
synthes
folateprna
respect
chimer
prnasirna
folateprna
mix
molar
ratio
presenc
mm
mg
prna
heterodim
produc
high
effici
confirm
nondenatur
page
fig
chimer
heterodim
gener
differ
monom
subunit
despit
replac
helix
sirna
control
determin
whether
chimer
complex
could
process
function
sirna
chimer
prnasirna
subject
treatment
recombin
dicer
known
function
process
long
doublestrand
premirna
sirna
vitro
vivo
carmel
hannon
plabel
chimer
prnasirna
complex
use
substrat
studi
harbor
dssirna
connect
prna
intermolecular
interact
domain
span
nt
fig
addit
poli
u
base
use
link
prna
backbon
sequenc
increas
facilit
fold
incub
prnasirna
complex
dicer
result
process
complex
dssirna
reveal
denatur
urea
page
fig
folat
receptor
overexpress
variou
type
cancer
cell
hela
cell
claycomb
et
al
holm
et
al
gener
absent
noncanc
cell
mef
cell
test
whether
folat
conjug
prna
molecul
guid
drug
deliveri
specif
target
cell
incub
hela
cell
presenc
folatefitc
conjug
use
mef
cell
control
h
incub
intracellular
distribut
fluoresc
signal
observ
fluoresc
microscop
found
hela
cell
subcultur
folat
defici
medium
much
stronger
green
fluoresc
signal
counterpart
subcultur
folatecontain
growth
medium
mef
cell
noncanc
cell
consid
folat
receptor
affect
either
medium
show
signal
fig
hela
cell
folat
receptorexpress
tumor
cell
also
suscept
infect
cell
use
model
system
evalu
chimer
prnasirna
antivir
studi
test
whether
antivir
activ
affect
link
prna
hela
cell
transfect
control
prnasirna
infect
make
comparison
free
also
use
transfect
hela
cell
lipofectamin
antivir
activ
prnasirna
measur
differ
method
shown
figur
rtpcr
detect
mrna
fig
western
blot
detect
protein
fig
demonstr
deliv
prna
strongli
inhibit
replic
compar
control
includ
prna
nt
vector
mut
prnasirnascr
antivir
activ
correl
well
data
obtain
morpholog
observ
show
cell
treat
less
cell
death
treat
control
prnasirna
fig
data
solidifi
viral
plaqu
assay
measur
infecti
viral
particl
mt
assay
measur
cell
viabil
fig
show
compar
level
control
approxim
decreas
pfu
product
detect
cultur
treat
free
littl
inhibit
replic
occur
mutat
scrambl
sirna
introduc
cell
fig
demonstr
treatment
could
maintain
cell
surviv
compar
cell
treat
prna
vector
control
cell
surviv
result
indic
chimer
remain
high
effici
antivir
activ
free
prna
reliabl
vehicl
deliv
therapeut
molecul
data
impli
chimer
correctli
process
dicer
function
dssirna
releas
specul
support
vitro
process
experi
demonstr
plabel
process
sirna
recombin
rnase
iiilik
ribonucleas
dicer
incub
fig
strategi
prna
heterodimermedi
gene
silenc
ligandmedi
cell
recognit
subsequ
intern
releas
function
sirna
knockdown
specif
gene
prna
heterodim
contain
folat
sirna
proteas
incub
rather
transfect
hela
cell
follow
infect
h
western
blot
analysi
indic
monom
prna
heterodim
complex
folateprna
strongli
inhibit
replic
compar
control
fig
viral
plaqu
assay
show
decreas
pfuml
compar
control
fig
addit
cell
viabil
assay
demonstr
cell
treat
either
prna
heterodim
complex
could
maintain
cell
surviv
compar
cell
treat
control
show
cell
surviv
fig
result
suggest
specif
knockdown
proteas
gene
achiev
folat
receptormedi
intern
monom
prna
heterodim
complex
absenc
transfect
reagent
drug
develop
one
critic
barrier
clinic
applic
drug
nonspecif
distribut
bodi
administr
although
variou
method
describ
deliv
drug
cell
method
accomplish
deliveri
nonspecif
nonspecif
deliveri
reduc
therapeut
effici
caus
harm
side
effect
also
wast
drug
result
high
cost
therefor
develop
effect
system
target
deliveri
therapeut
molecul
main
goal
present
studi
chose
sirna
target
gene
critic
proteas
involv
viral
life
cycl
pathogenesi
effect
drug
test
novel
deliveri
system
first
determin
whether
coval
linkag
replac
doubl
helix
region
end
backbon
sequenc
prna
affect
function
demonstr
achiev
similar
strong
activ
free
indic
sequenc
carri
prna
properli
fold
dsrna
helix
process
dicer
releas
function
enter
cell
increas
effici
activ
releas
dicer
two
addit
uridin
introduc
junction
increas
free
energi
fold
junction
area
singlestrand
loop
experi
indic
prna
molecul
employ
novel
categori
rna
vector
deliveri
therapeut
rna
molecul
specif
cell
recognit
silenc
target
gene
cell
two
featur
requir
effect
gene
therapi
construct
prna
dimer
carri
drug
ligand
simultan
satisfi
goal
main
goal
develop
new
system
sirna
specif
deliveri
target
cell
select
hela
cell
suscept
host
cancer
cell
line
test
system
sinc
almost
cancer
cell
folat
receptor
posit
cell
holm
et
al
toffoli
et
al
use
folat
ligand
guid
receptor
bind
intern
sirna
construct
folatelabel
chimer
monom
heterodim
complex
demonstr
first
time
ligandmedi
deliveri
sirna
carri
prna
vector
could
success
inhibit
viral
replic
prna
folat
found
molar
ratio
atp
could
result
high
yield
increas
label
effici
assembl
heterodim
complex
folateprna
magnesium
concentr
crucial
mg
mm
could
result
high
yield
dimer
confirm
previou
report
guo
et
al
concentr
may
also
import
stabil
dimer
deliveri
thu
maintain
concentr
deliveri
vivo
need
investig
prna
report
deliv
sirna
treat
cancer
sever
studi
guo
et
al
guo
et
al
howev
use
deliveri
sirna
treat
viral
infect
never
report
data
show
great
potenti
small
rna
molecul
effect
vector
target
deliveri
antivir
drug
larg
attribut
uniqu
characterist
guo
guo
besid
low
immunogen
result
smaller
size
often
use
viral
vector
thu
far
properti
spontan
form
dimer
trimer
hexim
array
render
capabl
carri
drug
ligand
one
multim
shu
et
al
case
multim
carri
combin
therapeut
molecul
andor
ligand
may
render
synergist
effect
gene
silenc
specif
target
potenti
simultan
deliv
multipl
therapeut
sequenc
may
effect
reduc
mutat
escap
drug
resist
viru
uniqu
critic
requir
antivir
drug
develop
virus
particularli
rna
virus
hiv
sarscov
influenza
viru
high
mutat
rate
drug
resist
major
barrier
treatment
viral
infect
difficult
develop
effect
vaccin
prevent
diseas
frequent
reemerg
anoth
challeng
achiev
target
drug
deliveri
use
system
search
specif
ligand
conjug
prna
use
folat
ligand
vitro
studi
hela
cell
establish
cell
line
studi
infect
happen
cancer
cell
express
high
level
folat
receptor
primari
pathogen
human
myocard
kim
et
al
aim
deliveri
drug
heart
inhibit
replic
date
effect
vector
specif
deliv
therapeut
organ
even
though
aav
vector
retroviru
vector
achiev
promis
outcom
big
dna
vector
high
immunogen
fechner
et
al
kim
et
al
present
studi
shown
promis
explor
possibl
use
small
prna
vehicl
transport
drug
heart
ligandreceptor
interact
ligand
target
heart
either
specif
myocardiumbind
peptid
receptor
ligand
peptid
viral
capsid
protein
current
search
ligand
laboratori
progress
synthesi
monom
heterodim
prnasirna
agaros
gel
electrophoresi
dna
fragment
use
vitro
transcript
cdna
fragment
amplifi
pcr
use
plasmid
encod
prna
sequenc
templat
primer
list
tabl
zhang
et
al
b
analysi
chimer
prna
transcript
denatur
page
prna
chimera
synthes
vitro
transcript
use
cdna
fragment
demonstr
contain
point
mutat
mut
middl
scrambl
scr
sirna
indic
respect
c
analysi
folatelabel
chimer
prna
denatur
page
folateprna
synthes
vitro
transcript
presenc
folateamp
demonstr
prna
heterodim
complex
format
nondenaturingpag
prnasirna
folateprna
dimer
mix
folateprna
control
prnasirna
buffer
contain
mm
mgcl
autoradiogram
show
process
chimer
dicer
chimer
prnasirna
label
p
incub
dicer
min
min
min
subject
electrophoresi
denatur
urea
polyacrylamid
gel
lane
plabel
rna
molecular
weight
marker
move
gel
note
sirna
move
slower
marker
probabl
due
extra
u
linker
made
dicer
cleavag
product
nt
specif
deliveri
folatefitc
conjug
hela
cell
via
interact
folic
acid
receptor
hela
cell
mef
cell
control
maintain
folic
aciddefici
rpmi
medium
two
week
subcultur
media
contain
without
contain
folat
respect
contain
folatefitc
conjug
incub
green
fluoresc
signal
observ
fluoresc
microscop
two
imag
field
antivir
evalu
deliv
folatelabel
prna
monom
heterodim
complex
incub
hela
cell
incub
folic
acid
defici
rpmi
medium
two
week
one
day
incub
hela
cell
passag
plate
second
day
hela
cell
incub
heterodim
folateprna
monom
infect
antivir
activ
evalu
western
blot
analysi
detect
protein
viral
plaqu
assay
detect
infecti
viral
particl
b
mt
assay
determin
cell
viabil
c
describ
figur
data
mean
valu
two
independ
experi
